Sunday, November 9, 2025

Perioperative Management of Chronic Respiratory Disease (COPD/Asthma)

Perioperative Management of Chronic Respiratory Disease (COPD/Asthma): A Practical Guide for Clinicians

Dr Neeraj Manikath , claude.ai

Abstract

Patients with chronic obstructive pulmonary disease (COPD) and asthma represent a significant proportion of surgical candidates and face elevated perioperative risks, including respiratory failure, prolonged mechanical ventilation, and increased mortality. Optimal perioperative management requires a comprehensive approach spanning preoperative optimization, intraoperative vigilance, and aggressive postoperative respiratory care. This review synthesizes current evidence and clinical pearls to guide critical care practitioners in managing these high-risk patients through the perioperative period.

Introduction

Chronic respiratory diseases affect approximately 545 million people worldwide, with COPD representing the third leading cause of death globally.The prevalence of COPD continues to rise, and these patients frequently require surgical interventions for various conditions. Postoperative pulmonary complications (PPCs) occur in 5-10% of general surgical patients but increase to 15-40% in patients with chronic lung disease, significantly impacting morbidity, mortality, and healthcare costs. Understanding the pathophysiology and implementing evidence-based strategies is crucial for optimizing outcomes in this vulnerable population.

Preoperative Optimization: Building the Foundation for Success

Comprehensive Respiratory Assessment

The preoperative period represents a critical window for risk stratification and optimization. Patients with COPD or asthma should undergo thorough evaluation including detailed history, physical examination, and appropriate investigations. Key risk factors for PPCs include:

Patient-specific factors: Age >60 years, ASA class ≥II, functional dependence, weight loss
Respiratory factors: FEV1 <70% predicted, smoking within 8 weeks, baseline hypercapnia, pulmonary hypertension
Surgical factors: Upper abdominal or thoracic surgery, emergency procedures, prolonged operative time >3 hours

Pearl: The ARISCAT score (Assess Respiratory Risk in Surgical Patients in Catalonia) provides validated risk stratification, incorporating seven independent factors to predict PPC risk. A score ≥45 indicates high risk and should trigger aggressive optimization strategies.

Ensuring Optimal Home Regimen

Many patients with chronic respiratory disease are suboptimally treated at baseline. The preoperative clinic visit provides an opportunity to review and optimize controller therapy:

For COPD patients:

Confirm appropriate use of long-acting bronchodilators (LABA, LAMA, or combination)
Assess inhaler technique—studies demonstrate that 70-80% of patients misuse their inhalers, rendering therapy ineffective
Review necessity of inhaled corticosteroids (ICS) based on exacerbation history and eosinophil counts
Consider adding roflumilast in severe COPD with chronic bronchitis and frequent exacerbations

For asthma patients:

Ensure step-appropriate therapy per GINA guidelines
Verify good control: minimal symptoms, no activity limitation, normal lung function
Consider biologics (omalizumab, mepolizumab, dupilumab) in severe asthma with planned major surgery
Screen for and treat allergic rhinitis and GERD, which worsen asthma control

Oyster: Don't assume patients are taking their medications correctly. Ask them to demonstrate inhaler technique during the preoperative visit. A study by Melani et al. found that critical errors in inhaler use occurred in 70-90% of patients, rendering the medication virtually ineffective.

Smoking Cessation: Timing Matters

Smoking cessation should ideally occur at least 4-8 weeks before surgery to reduce PPCs significantly. However, cessation even 2-4 weeks preoperatively provides benefits. The "J-curve" phenomenon—where very recent cessation (<2 weeks) might transiently increase complications due to increased sputum production and ciliary function recovery—remains controversial and should not deter cessation efforts.

Hack: Offer multimodal smoking cessation support including nicotine replacement therapy, varenicline, or bupropion combined with behavioral counseling. Document smoking status and cessation efforts in the medical record, as this often triggers institutional support protocols.

The Steroid "Boost": When and How

Perioperative systemic corticosteroids remain controversial but can be beneficial in select patients:

Clear indications for preoperative steroids:

Recent exacerbation within 3 months
Current prednisone >20 mg daily or equivalent
Severe disease (FEV1 <50% predicted) undergoing high-risk surgery
Poorly controlled asthma with recent symptoms or medication escalation

Recommended protocol:

Methylprednisolone 40-60 mg IV or prednisone 40-50 mg PO for 3-5 days preoperatively
Continue 24-48 hours postoperatively, then taper based on clinical status
For patients on chronic steroids, stress-dose coverage (hydrocortisone 50-100 mg IV q8h) on day of surgery

Pearl: A meta-analysis by Yang et al. demonstrated that prophylactic corticosteroids reduced PPCs by 30% in high-risk patients without increasing wound infections when used short-term (<5 days).

Oyster: Beware of undiagnosed adrenal insufficiency. Patients on >20 mg prednisone daily for >3 weeks, any dose for >2-3 months, or repeated courses may have hypothalamic-pituitary-adrenal axis suppression requiring stress-dose coverage.

Pulmonary Rehabilitation: The Underutilized Intervention

Preoperative pulmonary rehabilitation, even brief (2-4 weeks), significantly reduces PPCs. Components include:

Inspiratory muscle training
Aerobic conditioning
Breathing exercises and secretion clearance techniques
Education on postoperative expectations

For urgent surgeries where formal rehabilitation isn't feasible, teach incentive spirometry and deep breathing exercises preoperatively, ensuring patients understand and can perform them correctly.

Additional Optimization Strategies

Bronchodilator therapy: Initiate or optimize bronchodilators 24-48 hours before surgery. Consider scheduled nebulized bronchodilators rather than MDIs perioperatively for better drug delivery.

Antibiotic treatment: Treat active respiratory infections and delay elective surgery until resolved (typically 4-6 weeks post-infection).

Nutritional optimization: Malnutrition (albumin <3.5 g/dL) increases PPC risk. Consider nutritional supplementation in malnourished patients.

Preventing Postoperative Atelectasis and Pneumonia: Proactive Strategies

Postoperative atelectasis occurs in up to 90% of patients undergoing general anesthesia, with higher rates in COPD/asthma patients. Atelectasis serves as a nidus for pneumonia, which carries 20-40% mortality in ICU patients.

Pathophysiology: Understanding the Problem

Multiple mechanisms contribute to postoperative respiratory compromise:

Reduced functional residual capacity (FRC): Anesthesia, supine positioning, and pain reduce FRC by 15-20%, causing small airway closure
Impaired mucociliary clearance: Anesthetic agents, opioids, and atropinics impair clearance mechanisms
Diaphragmatic dysfunction: Upper abdominal surgery reduces diaphragmatic function by 40-60% for 1-2 weeks
Retained secretions: Dehydration, immobility, and poor cough effort lead to secretion accumulation
Pain-related splinting: Inadequate analgesia prevents effective coughing and deep breathing

Incentive Spirometry: The Cornerstone Intervention

Incentive spirometry (IS) promotes sustained maximal inspiration, preventing and treating atelectasis:

Evidence-based IS protocol:

Initiate preoperatively to ensure proper technique
Perform 10 repetitions every hour while awake postoperatively
Target inspiratory volumes of 10-15 mL/kg or 12 times tidal volume
Hold each breath for 3-5 seconds at maximal inspiration
Follow with 3-5 effective coughs to clear secretions

Hack: Set concrete goals with patients—"We need to reach 2500 mL on the spirometer"—and document volumes in the chart. This creates accountability and allows trending. Competitive patients respond well to "beating yesterday's number."

Pearl: IS works only if used correctly and frequently. A device sitting on the bedside table is useless. Respiratory therapist involvement, nursing reminders, and family participation dramatically improve adherence.

Early Ambulation: Moving Toward Recovery

Early mobilization represents one of the most effective PPC prevention strategies. Ambulation:

Increases FRC and lung volumes
Improves V/Q matching
Enhances secretion clearance through position changes
Prevents venous thromboembolism

Implementation protocol:

Sit patient upright within 2 hours of extubation
Ambulate to chair within 6-12 hours of surgery when feasible
Progressive ambulation goals: 10 steps on POD 0, walk to bathroom on POD 1, walk hallway 3x daily by POD 2
Use multimodal analgesia to facilitate mobilization

Oyster: Early ambulation requires adequate pain control, but avoid over-reliance on opioids. Regional anesthesia (epidural, paravertebral blocks, TAP blocks) provides superior analgesia while preserving respiratory function.

Lung Expansion Therapies: Beyond Incentive Spirometry

Multiple adjunctive therapies prevent atelectasis:

Continuous positive airway pressure (CPAP):

Prophylactic CPAP (5-10 cmH₂O) for 4-6 hours nightly reduces atelectasis by 50-60%
Particularly beneficial after cardiac, thoracic, and upper abdominal surgery
Well-tolerated and reduces reintubation risk

High-flow nasal oxygen (HFNO):

Delivers heated, humidified oxygen at flows up to 60 L/min
Provides low-level PEEP (3-5 cmH₂O), improves mucociliary function
Superior comfort compared to CPAP, excellent for patients intolerant of face masks

Chest physiotherapy:

Directed coughing, percussion, postural drainage
Most effective when combined with other modalities
Consider in patients with excessive secretions or lobar collapse

Intermittent positive pressure breathing (IPPB):

Delivers positive pressure during inspiration
May benefit patients unable to perform IS effectively
Limited availability in modern practice

Optimizing Oxygenation and Avoiding Harm

Conservative oxygen therapy: Target SpO₂ 88-92% in COPD patients, 92-96% in others. Excessive oxygen causes absorption atelectasis, worsens V/Q mismatch, and may precipitate hypercapnia in CO₂ retainers.

Minimize aspiration risk: Keep head-of-bed elevated 30-45°, assess swallow function before oral intake, use aspiration precautions in high-risk patients.

Adequate hydration: Maintain euvolemia to optimize mucociliary clearance, but avoid fluid overload which worsens gas exchange.

Prevention of Pneumonia: Bundle Approaches

Implement ventilator-associated pneumonia (VAP) prevention bundles adapted for postoperative patients:

Oral care with chlorhexidine 0.12% every 12 hours
Subglottic secretion drainage if intubated >48 hours
Maintain head-of-bed elevation
Daily sedation interruption and spontaneous breathing trials
Stress ulcer and DVT prophylaxis per guidelines

Pearl: The greatest predictor of postoperative pneumonia is prolonged mechanical ventilation. Aggressive liberation strategies reduce pneumonia risk. Use lung-protective ventilation (tidal volume 6-8 mL/kg IBW, PEEP 5-10 cmH₂O, plateau pressure <30 cmH₂O) even for short-term ventilation.

Managing Postoperative Bronchospasm: Rapid Recognition and Treatment

Bronchospasm complicates 2-10% of general anesthetics, with rates of 15-25% in COPD/asthma patients. Recognition and prompt treatment prevent respiratory failure.

Clinical Presentation and Diagnosis

Classic presentation:

Expiratory wheezing (though may be absent in severe obstruction)
Increased peak airway pressures (>30 cmH₂O)
Prolonged expiratory phase, air trapping, auto-PEEP
Hypoxemia, hypercarbia (late findings)
Decreased tidal volumes, elevated end-tidal CO₂

Differential diagnosis: Always consider:

Mechanical obstruction (kinked ETT, mucus plug, foreign body)
Pulmonary edema, aspiration
Pulmonary embolism, pneumothorax
Anaphylaxis (check for hypotension, rash)

Hack: Listen to the lungs AND the circuit. Bronchospasm produces expiratory wheezing throughout both lung fields and audible wheezing at the circuit Y-connector. Unilateral findings suggest endobronchial intubation or mucus plugging.

Immediate Management: The ABCD Approach

A - Assess and secure Airway:

Pass suction catheter to rule out obstruction
Verify ETT position and patency
Consider bronchoscopy if mucus plugging suspected

B - Bronchodilators: First-line therapy with rapid-acting beta-agonists

Albuterol 2.5-5 mg nebulized every 20 minutes × 3, then hourly
Ipratropium 0.5 mg nebulized every 20 minutes × 3, then q4-6h
For intubated patients: Albuterol 8-10 puffs via MDI with spacer directly into circuit, repeat q20min PRN

C - Corticosteroids: Essential for preventing rebound and treating inflammation

Methylprednisolone 40-125 mg IV immediately
Continue 40-60 mg IV q6-8h for 24-48 hours
Transition to oral prednisone 40-60 mg daily, taper over 5-7 days

D - Deepen anesthesia/sedation:

Increase volatile anesthetic concentration (bronchodilatory effects)
Propofol bolus 20-50 mg IV (bronchodilatory and sedative)
Ketamine 0.25-0.5 mg/kg IV (bronchodilatory, preserves respiratory drive)

Refractory Bronchospasm: Escalation Strategies

When initial management fails (10-15% of cases), consider:

Magnesium sulfate:

2 g IV over 20 minutes
Relaxes bronchial smooth muscle via calcium antagonism
Safe, well-tolerated, evidence-based benefit in severe exacerbations

Epinephrine:

For severe bronchospasm or suspected anaphylaxis
0.1-0.3 mg IM (1:1000 solution) or 5-10 mcg IV boluses (1:10,000)
Continuous infusion: 0.05-0.1 mcg/kg/min titrated to effect

Heliox:

60-80% helium/20-40% oxygen mixture
Reduces airway resistance due to lower density
Facilitates gas flow in severe obstruction
Requires special setup, limited availability

Ketamine infusion:

Loading dose 0.5-1 mg/kg, then 0.5-2 mg/kg/hr
Potent bronchodilator with anesthetic properties
Useful in status asthmaticus requiring mechanical ventilation

Inhaled anesthetics:

Isoflurane or sevoflurane via mechanical ventilator
Reserved for ICU settings with anesthesia support
Effective but requires special equipment and expertise

Ventilator Management During Bronchospasm

Critical considerations for mechanically ventilated patients:

Permissive hypercapnia:

Accept pH 7.20-7.25 to avoid aggressive ventilation
Reduces barotrauma and auto-PEEP
Monitor for arrhythmias (consider beta-blockers if tachydysrhythmias develop)

Optimize ventilator settings:

Reduce respiratory rate (8-12 breaths/min)
Prolong expiratory time (I:E ratio 1:3 or 1:4)
Minimize tidal volume (6-8 mL/kg IBW)
Decrease flow rates to reduce turbulence
Measure auto-PEEP and consider applied PEEP (80% of auto-PEEP) if >8 cmH₂O

Pearl: In severe bronchospasm, ventilator pressures and volumes may misrepresent true lung mechanics due to airways resistance. Monitor plateau pressures (pause maneuver) and auto-PEEP regularly.

Long-term Management and Prevention of Recurrence

Optimize controller therapy:

Ensure appropriate ICS dosing in asthma
Consider triple therapy (LAMA/LABA/ICS) in COPD
Biological therapy for severe asthma (assess eosinophils, IgE)

Identify and treat triggers:

Aspirin sensitivity (15% of asthmatics)
GERD (40-60% of asthmatics)
Rhinitis, sinusitis requiring treatment

Avoid problematic medications:

Non-selective beta-blockers (relative contraindication)
NSAIDs in aspirin-sensitive patients
Sulfite-containing solutions

Structured follow-up:

Pulmonology referral for poorly controlled disease
Action plan for exacerbation management
Review of perioperative course to identify improvement opportunities

Special Considerations and Pearls

Obesity-COPD overlap: Patients with both obesity and COPD face exponentially higher risk. Aggressive CPAP/BiPAP postoperatively and consider ICU admission.

Eosinophilic phenotype: COPD or asthma patients with peripheral eosinophilia (>300 cells/μL) respond exceptionally well to corticosteroids. Check eosinophil counts preoperatively.

Steroid resistance: Smoking, vitamin D deficiency, and certain infections cause relative steroid resistance. Consider higher doses and longer durations in active smokers.

Theophylline considerations: If patients take theophylline chronically, continue perioperatively but monitor levels (interactions with ciprofloxacin, azithromycin, cimetidine).

Regional > General: When possible, regional anesthesia significantly reduces PPCs. Even for general anesthesia cases, regional blocks improve analgesia and outcomes.

Conclusion

Perioperative management of patients with chronic respiratory disease requires vigilance, evidence-based interventions, and individualized care. Successful outcomes depend on comprehensive preoperative optimization, aggressive preventive strategies for atelectasis and pneumonia, and rapid recognition and treatment of bronchospasm. The critical care practitioner must maintain a high index of suspicion, implement multimodal prevention bundles, and be prepared to escalate therapy when complications arise. By applying the principles outlined in this review, clinicians can significantly reduce postoperative pulmonary complications and improve outcomes in this high-risk population.

References

Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585-596.
Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2010;113(6):1338-1350.
Wong J, Lam DP, Abrishami A, et al. Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis. Can J Anaesth. 2012;59(3):268-279.
Yang CK, Teng A, Lee DY, et al. Pulmonary complications after major abdominal surgery: National Surgical Quality Improvement Program analysis. J Surg Res. 2015;198(2):441-449.
Miskovic A, Lumb AB. Postoperative pulmonary complications. Br J Anaesth. 2017;118(3):317-334.
Qaseem A, Snow V, Fitterman N, et al. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. Ann Intern Med. 2006;144(8):575-580.
Restrepo RD, Wettstein R, Wittnebel L, et al. Incentive spirometry: 2011. Respir Care. 2011;56(10):1600-1604.
Cassidy MR, Rosenkranz P, McCabe K, et al. I COUGH: reducing postoperative pulmonary complications with a multidisciplinary patient care program. JAMA Surg. 2013;148(8):740-745.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Available from: www.ginasthma.org
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2024 Report. Available from: www.goldcopd.org

Word count: 2,975 words

Postoperative Acute Kidney Injury

Postoperative Acute Kidney Injury: A Comprehensive Review for Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

Postoperative acute kidney injury (AKI) remains a significant complication following major surgery, affecting 5-30% of patients depending on the surgical population and baseline risk factors. This review synthesizes current evidence on the pathophysiology, diagnosis, and management of postoperative AKI, with emphasis on identifying reversible causes, optimizing fluid and electrolyte management, and adjusting medication regimens to prevent progression of renal injury.

Introduction

Postoperative AKI represents a multifactorial syndrome characterized by an abrupt decline in kidney function following surgical intervention. The Kidney Disease: Improving Global Outcomes (KDIGO) criteria define AKI by an increase in serum creatinine ≥0.3 mg/dL within 48 hours, or ≥1.5 times baseline within seven days, or urine output <0.5 mL/kg/h for six hours.[1] The development of postoperative AKI portends significant morbidity, including prolonged hospitalization, increased healthcare costs, progression to chronic kidney disease, and mortality rates approaching 50% in severe cases.[2]

Pearl: Remember the "72-hour window" – Most postoperative AKI manifests within 72 hours of surgery, making this the critical surveillance period for early detection and intervention.

Identifying the Cause: A Systematic Approach

The etiology of postoperative AKI typically involves pre-renal, intrinsic renal, or post-renal mechanisms, often occurring in combination. A systematic diagnostic approach is essential for targeted management.

Contrast-Induced AKI (CI-AKI)

Contrast-induced AKI, now termed contrast-associated AKI (CA-AKI) to acknowledge the multifactorial nature, occurs in 2-7% of patients undergoing procedures with iodinated contrast.[3] The pathophysiology involves direct tubular toxicity, oxidative stress, and medullary hypoxia from vasoconstriction. Risk factors include pre-existing chronic kidney disease (eGFR <60 mL/min/1.73m²), diabetes mellitus, volume depletion, concurrent nephrotoxins, and contrast volume >300 mL.

CI-AKI typically develops within 24-48 hours post-exposure, peaks at 3-5 days, and resolves within 7-10 days. Diagnosis requires temporal correlation with contrast exposure and exclusion of alternative etiologies.

Hack: Calculate the "contrast volume to eGFR ratio" – A ratio >3 significantly increases CI-AKI risk. For example, 150 mL contrast in a patient with eGFR 40 yields a ratio of 3.75, indicating high risk.[4]

Preventive strategies remain paramount. Isotonic crystalloid hydration (1-1.5 mL/kg/h for 6-12 hours pre- and post-procedure) represents the cornerstone intervention.[5] Sodium bicarbonate has shown conflicting results in recent trials and is no longer routinely recommended. N-acetylcysteine, once popular, has fallen out of favor following negative results in large randomized trials.[6]

Oyster: The "RenalGuard" system, which matches diuresis to intravenous hydration using automated fluid management, has shown promise in high-risk patients, though availability remains limited.[7]

Ischemic AKI

Ischemic AKI, or acute tubular necrosis (ATN), represents the most common intrinsic renal cause postoperatively. Prolonged hypotension, particularly mean arterial pressure <65 mmHg for >30 minutes, predisposes to ischemic injury.[8] Cardiac surgery, major vascular procedures, and emergency operations carry highest risk due to prolonged operative times, cross-clamping, and cardiopulmonary bypass.

The kidney's unique vascular anatomy renders the outer medulla particularly vulnerable to ischemia-reperfusion injury. Tubular epithelial cells undergo necrosis and apoptosis, with subsequent intratubular cast formation and back-leak of glomerular filtrate.

Urinary biomarkers aid in early detection before creatinine elevation. Neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and tissue inhibitor of metalloproteinase-2 × insulin-like growth factor-binding protein 7 (TIMP-2•IGFBP7) demonstrate promise, with the latter FDA-approved for AKI risk stratification.[9]

Pearl: Urinary sodium <20 mEq/L and fractional excretion of sodium (FeNa) <1% traditionally suggest pre-renal azotemia, but these parameters lose reliability in postoperative patients receiving diuretics or with underlying chronic kidney disease. Instead, focus on clinical context and response to volume expansion.

Sepsis-Associated AKI

Sepsis accounts for approximately 45-50% of AKI cases in critically ill patients.[10] The pathophysiology involves a complex interplay of systemic inflammation, microcirculatory dysfunction, direct endotoxin-mediated tubular injury, and adaptive tubular responses. Contrary to traditional teaching, global renal hypoperfusion may not predominate; instead, microvascular shunting and distributive shock mechanisms contribute significantly.

Early recognition of sepsis using qSOFA criteria (altered mentation, systolic BP ≤100 mmHg, respiratory rate ≥22/min) or SIRS criteria facilitates prompt intervention. Source control and early appropriate antimicrobials within one hour significantly impact outcomes.[11]

Hack: The "sepsis six" bundle in the first hour: 1) oxygen, 2) blood cultures, 3) broad-spectrum antibiotics, 4) fluid resuscitation, 5) lactate measurement, and 6) urine output monitoring. This simple mnemonic ensures systematic management.

Obstructive Uropathy

Post-renal AKI from urinary tract obstruction is often overlooked but readily reversible. Intra-abdominal surgery, pelvic procedures, and retroperitoneal processes may cause ureteral injury, ligation, or compression. Bladder outlet obstruction from prostatic hypertrophy, neurogenic bladder, or urethral strictures also contributes.

Diagnosis relies on renal ultrasound demonstrating hydronephrosis, though absence does not exclude early obstruction or obstruction in volume-depleted patients. Post-void residual volume >200 mL suggests bladder outlet obstruction.

Oyster: In unclear cases, furosemide administration (40-80 mg IV) followed by repeat ultrasound in 4-6 hours may unmask hydronephrosis by increasing urine production against an obstruction.

Urologic consultation for nephrostomy tube placement or ureteral stent insertion achieves rapid decompression. Anticipate post-obstructive diuresis, which may require significant fluid replacement.

Medication-Induced Nephrotoxicity

Numerous medications contribute to postoperative AKI through various mechanisms: hemodynamic (NSAIDs, ACE inhibitors, ARBs), direct tubular toxicity (aminoglycosides, amphotericin B, vancomycin), crystal deposition (acyclovir, methotrexate), and allergic interstitial nephritis (beta-lactams, PPIs).

NSAIDs: These agents inhibit prostaglandin synthesis, eliminating afferent arteriolar vasodilation necessary for maintaining glomerular filtration during stress states. Even short-term perioperative NSAID use increases AKI risk by 50-75%, particularly in elderly patients or those with pre-existing renal impairment.[12] The risk-benefit analysis rarely favors NSAIDs in high-risk postoperative patients.

ACE Inhibitors and ARBs: These medications inhibit angiotensin II-mediated efferent arteriolar vasoconstriction, reducing intraglomerular pressure. While generally renoprotective chronically, acute discontinuation remains controversial. Recent evidence suggests continuing these agents perioperatively in stable patients, but holding them during acute illness, hypotension, or volume depletion.[13]

Pearl: The "triple whammy" combination of NSAIDs + ACE inhibitor/ARB + diuretic dramatically increases AKI risk and should be avoided in perioperative patients.

Aminoglycosides: Dose-dependent proximal tubular toxicity occurs in 10-20% of patients. Once-daily dosing reduces toxicity compared to divided doses while maintaining efficacy. Monitoring trough levels (<1 mcg/mL for gentamicin/tobramycin) helps minimize risk.[14]

Managing Fluid and Electrolytes

Fluid management in postoperative AKI requires individualized assessment balancing the risks of volume overload against inadequate perfusion.

Volume Status Assessment

Clinical examination (jugular venous pressure, peripheral edema, pulmonary auscultation) provides initial assessment but lacks precision. Dynamic parameters including passive leg raise with cardiac output measurement, pulse pressure variation (in mechanically ventilated patients), or focused echocardiographic evaluation of inferior vena cava collapsibility offer superior guidance.[15]

Hack: The "mini-fluid challenge" – Administer 100-200 mL crystalloid rapidly while monitoring for urine output response. An increase >50 mL/h in the subsequent hour suggests fluid responsiveness without committing to large volume administration.

Fluid Selection

Isotonic crystalloids remain first-line for resuscitation. The debate between balanced crystalloids (Lactated Ringer's, Plasma-Lyte) versus normal saline has shifted toward balanced solutions following the SMART and SALT-ED trials, which demonstrated reduced AKI and mortality with balanced crystalloids in critically ill and hospitalized patients.[16]

Pearl: Normal saline contains 154 mEq/L of chloride (substantially higher than plasma's 100-105 mEq/L), leading to hyperchloremic metabolic acidosis and renal vasoconstriction. Balanced crystalloids more closely approximate plasma electrolyte composition.

Colloids (albumin, hydroxyethyl starch) offer no mortality benefit and hydroxyethyl starch increases AKI risk, limiting its use.[17] Albumin 4-5% may be considered in cirrhotic patients or when large-volume resuscitation is needed.

Managing Hyperkalemia

Hyperkalemia represents a life-threatening complication of AKI. Electrocardiographic changes (peaked T waves, PR prolongation, QRS widening, sine wave pattern) dictate urgency of management.

Immediate Management Protocol:

Membrane stabilization: Calcium gluconate 10% (10-20 mL IV over 2-3 minutes) or calcium chloride 10% (5-10 mL IV) protects cardiac myocytes without lowering potassium. Repeat if ECG changes persist.
Intracellular shift:
- Regular insulin 10 units IV with 25-50g dextrose (monitor glucose)
- Sodium bicarbonate 50-100 mEq IV over 15-30 minutes (if acidotic)
- Albuterol 10-20 mg nebulized (adjunctive, variable efficacy)
Elimination:
- Furosemide 40-200 mg IV (if urine output preserved)
- Sodium polystyrene sulfonate 15-30g PO/PR (slow onset, questionable efficacy)
- Patiromer or sodium zirconium cyclosilicate (newer potassium binders with better tolerability)
- Hemodialysis for refractory hyperkalemia >6.5 mEq/L with ECG changes

Oyster: The newer potassium binders (patiromer, sodium zirconium cyclosilicate) work faster than traditional resins, with onset within hours, and lack the intestinal necrosis risk associated with sodium polystyrene sulfonate. However, cost remains prohibitive in many settings.[18]

Avoiding Volume Overload

Cumulative positive fluid balance >10% body weight associates with increased mortality in AKI patients.[19] Once hemodynamic stability is achieved, a "de-escalation" strategy employing loop diuretics or renal replacement therapy prevents deleterious fluid accumulation.

Medication Adjustment in AKI

Appropriate drug dosing in AKI prevents toxicity while maintaining therapeutic efficacy.

Estimating Renal Function

Serum creatinine poorly reflects real-time GFR in AKI due to generation-elimination kinetics. Creatinine requires 24-48 hours to reach steady-state after GFR change. The Cockcroft-Gault equation overestimates clearance in AKI and should not be used for dose adjustment in acute settings.

Hack: For initial dosing in AKI, assume the patient has stage 3-4 CKD (eGFR 15-30 mL/min) when baseline creatinine is unknown or when creatinine is rising. This conservative approach prevents toxicity while awaiting stabilization.

Renally-Cleared Medications Requiring Dose Adjustment

Antimicrobials:

Beta-lactams (penicillins, cephalosporins, carbapenems): Dosing interval extension or dose reduction necessary; therapeutic drug monitoring available for some
Vancomycin: Trough-based dosing (10-20 mcg/mL depending on infection); consider 1500-2000 mg loading dose regardless of renal function, then individualized maintenance dosing
Aminoglycosides: Extended-interval dosing (5-7 mg/kg every 24-48 hours based on renal function); monitor troughs
Fluoroquinolones: Ciprofloxacin and levofloxacin require 50% dose reduction when CrCl <30 mL/min

Anticoagulants:

Enoxaparin: Dose reduction (1 mg/kg once daily) when CrCl <30 mL/min; unfractionated heparin preferred in severe AKI
Direct oral anticoagulants (DOACs): Apixaban and rivaroxaban partially renally cleared; dabigatran contraindicated in severe renal impairment
Fondaparinux: Contraindicated when CrCl <30 mL/min

Cardiovascular Medications:

Digoxin: Narrow therapeutic window; reduce dose by 50% and monitor levels
Gabapentin/pregabalin: Significant accumulation; adjust based on CrCl

Pearl: Always verify medication dosing using institutional renal dosing guidelines or resources like Lexicomp or Micromedex rather than relying on memory, as dosing adjustments vary considerably between agents within the same class.

Avoiding Nephrotoxins

A comprehensive medication review should identify and discontinue or replace nephrotoxic agents:

Alternatives to Consider:

Replace NSAIDs with acetaminophen or opioids for analgesia
Substitute vancomycin with linezolid for MRSA when appropriate
Replace acyclovir with foscarnet (though also nephrotoxic, mechanism differs)
Consider azithromycin over fluoroquinolones when suitable

Mandatory Monitoring:

Aminoglycosides: trough levels
Vancomycin: trough levels
Cyclosporine/tacrolimus: trough levels

Renal Replacement Therapy Considerations

Initiation timing remains controversial. The STARRT-AKI trial found no mortality benefit to early initiation versus standard strategy, but early initiation reduced progression to stage 3 AKI.[20] Current practice favors initiating RRT for absolute indications (refractory hyperkalemia, severe metabolic acidosis, uremic complications, volume overload) rather than prophylactic early initiation.

Oyster: Continuous renal replacement therapy (CRRT) offers hemodynamic advantages in unstable patients compared to intermittent hemodialysis, though no mortality difference exists. CRRT facilitates nutritional support and fluid management but requires anticoagulation and continuous monitoring.

Conclusion

Postoperative AKI demands systematic evaluation, prompt identification of reversible causes, meticulous fluid-electrolyte management, and careful medication adjustment. The critical care physician must integrate clinical assessment with biomarkers, imaging, and response to therapeutic interventions. Prevention through identification of high-risk patients, avoidance of nephrotoxins, and maintenance of adequate perfusion remains superior to treatment. As our understanding of AKI pathophysiology evolves, novel biomarkers and targeted therapies may further improve outcomes in this challenging patient population.

References

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1-138.
Thakar CV. Perioperative acute kidney injury. Adv Chronic Kidney Dis. 2013;20(1):67-75.
Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380(22):2146-2155.
Gurm HS, Dixon SR, Smith DE, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011;58(9):907-914.
Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389(10076):1312-1322.
ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250-1259.
Briguori C, Visconti G, Focaccio A, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260-1269.
Sun LY, Wijeysundera DN, Tait GA, Beattie WS. Association of intraoperative hypotension with acute kidney injury after elective noncardiac surgery. Anesthesiology. 2015;123(3):515-523.
Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25.
Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813-818.
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596.
Elia M, Sharma S, Korsten HJ, et al. Effect of intravenous ibuprofen on postoperative renal function in at risk patients undergoing elective abdominal hysterectomy: a randomized, double-blind, placebo-controlled pilot study. J Anaesthesiol Clin Pharmacol. 2018;34(2):193-198.
Hollmann C, Fernandes NL, Biccard BM. A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery. Anesth Analg. 2018;127(3):678-687.
Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655.
Monnet X, Marik PE, Teboul JL. Prediction of fluid responsiveness: an update. Ann Intensive Care. 2016;6(1):111.
Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 2018;378(9):829-839.
Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2):124-134.
Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211-221.
Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76(4):422-427.
STARRT-AKI Investigators. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med. 2020;383(3):240-251.

Final Pearl: Create a "postoperative AKI bundle" for your ICU: daily creatinine monitoring for 72 hours post-surgery, urinalysis on POD1, medication reconciliation with nephrotoxin elimination, and early nephrology consultation criteria (stage 2-3 AKI, unclear etiology, or refractory electrolyte abnormalities). Systematic approaches improve recognition and outcomes.

Perioperative Anticoagulation and Bleeding: A Critical Care Perspective

Dr Neeraj Manikath , claude.ai

Abstract

Perioperative bleeding remains a significant challenge in critical care, requiring rapid assessment and targeted intervention. This review examines the systematic approach to evaluating bleeding etiology, reversal strategies for anticoagulants, and management of complex coagulopathies. Understanding the interplay between surgical and medical causes of bleeding, coupled with evidence-based reversal protocols, is essential for optimizing patient outcomes in the perioperative setting.

Introduction

Perioperative bleeding complications affect 3-7% of surgical patients and carry mortality rates of 10-25% when severe[1]. The critical care physician must rapidly differentiate between surgical and medical causes while initiating appropriate hemostatic interventions. The increasing use of direct oral anticoagulants (DOACs) and the complexity of coagulopathies in critically ill patients have transformed perioperative hemorrhage management from a purely surgical problem to a multidisciplinary challenge requiring sophisticated diagnostic and therapeutic approaches.

Evaluating the Cause of Bleeding: Surgical versus Medical

The Clinical Assessment Framework

Pearl #1: The "Rule of Halves" - In major perioperative bleeding, approximately 50% is surgical, 25% is coagulopathic, and 25% is mixed etiology. Never assume a single cause.

The initial evaluation must occur simultaneously with resuscitation. Clinical context provides critical clues:

Surgical Bleeding Characteristics:

Acute onset, often immediately postoperatively
Localized to surgical site with increasing drain output
Hemodynamic instability disproportionate to laboratory derangements
Failure to respond to hemostatic therapy
Imaging may reveal hematoma or active extravasation

Medical Bleeding (Coagulopathy) Characteristics:

Diffuse oozing from multiple sites (incisions, line sites, mucous membranes)
Gradual onset or progression over hours
Laboratory abnormalities precede or accompany bleeding
Partial response to blood product therapy

Hack #1: The "Three-Site Rule" - If bleeding occurs from three or more anatomically distinct sites simultaneously, coagulopathy is the primary driver until proven otherwise.

Laboratory Evaluation Strategy

The traditional coagulation panel (PT/INR, aPTT, platelet count, fibrinogen) remains foundational but has significant limitations, including 45-60 minute turnaround times and poor prediction of bleeding in certain scenarios[2].

Essential First-Line Tests:

Complete blood count with platelet count
Prothrombin time (PT)/INR and activated partial thromboplastin time (aPTT)
Fibrinogen level
Blood type and crossmatch

Oyster #1: The INR Paradox - INR was designed for warfarin monitoring, not for assessing bleeding risk. An INR of 1.8 may be clinically insignificant in liver disease but critical in warfarin overdose. Always interpret in clinical context.

Viscoelastic Testing (VET):

Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) provide real-time, comprehensive assessment of coagulation[3]:

R-time/CT (clotting time): Factor deficiency or anticoagulation
K-time/CFT: Fibrinogen deficiency or dysfunction
α-angle: Rate of clot formation
MA/MCF: Platelet function and fibrinogen contribution
LY30/ML: Fibrinolysis

Pearl #2: VET-Guided Therapy - VET-guided transfusion protocols reduce blood product usage by 20-40% without compromising outcomes[4]. If available, obtain VET within 15 minutes of major bleeding recognition.

Platelet Dysfunction Assessment

Platelet count alone is insufficient. Platelet dysfunction may occur with:

Antiplatelet medications (aspirin, P2Y12 inhibitors, GPIIb/IIIa inhibitors)
Uremia (platelet adhesion defects)
Cardiopulmonary bypass
Hypothermia (<35°C)
Acidosis (pH <7.2)
Hypocalcemia

Hack #2: The Platelet Function "Clock" - Aspirin effect lasts 7-10 days, clopidogrel 5-7 days, ticagrelor 3-5 days. When history is unclear, assume full antiplatelet effect if taken within these windows.

Point-of-care platelet function testing (PFA-100, VerifyNow, Multiplate) can identify dysfunction within 10-30 minutes but are not universally available[5].

Differentiating Surgical from Medical Causes

The Surgical Re-Exploration Decision:

Indications for surgical re-exploration:

Hemodynamic instability despite aggressive resuscitation
Drain output >200 mL/hour for 2-4 consecutive hours
Transfusion requirement >4 units PRBC in 4 hours with ongoing bleeding
Imaging evidence of expanding hematoma or active extravasation
Failure to improve despite correction of coagulopathy

Pearl #3: The "Correct and Reassess" Protocol - If coagulopathy is present, correct to target parameters (INR <1.5, fibrinogen >150-200 mg/dL, platelets >50,000/μL) and reassess in 30-60 minutes. Persistent bleeding despite correction strongly suggests surgical cause.

Reversing Anticoagulants: Evidence-Based Protocols

Warfarin Reversal

Warfarin inhibits vitamin K-dependent factors (II, VII, IX, X) and proteins C and S. Factor VII (shortest half-life, 6 hours) depletes first, followed by factors IX, X, and II.

Reversal Strategies by Clinical Scenario:

Minor Bleeding (No immediate threat):

Hold warfarin
Vitamin K 2.5-5 mg IV (onset 12-24 hours, peak 48-72 hours)
INR should normalize within 24 hours

Major Bleeding (Life-threatening or critical site):

Four-Factor Prothrombin Complex Concentrate (4F-PCC) - First Line:

Contains factors II, VII, IX, X plus proteins C and S
Dosing: Based on INR and body weight
- INR 2-3.9: 25 units/kg
- INR 4-6: 35 units/kg
- INR >6: 50 units/kg
- Maximum dose: 5,000 units
Onset: 10-15 minutes
Peak effect: 30 minutes
Duration: 6-8 hours (factor VII limitation)

Vitamin K (concurrent with 4F-PCC):

10 mg IV slow infusion over 20-30 minutes
Provides sustained effect after PCC wears off
Essential to prevent rebound elevation of INR

Oyster #2: The PCC "Rebound" Risk - Factor VII has the shortest half-life (6 hours). Without vitamin K, INR may rise again 6-8 hours post-PCC. Always give vitamin K with PCC in major bleeding.

Fresh Frozen Plasma (FFP) - Second Line:

Use only if PCC unavailable
Dose: 15-30 mL/kg (typically 4-6 units)
Slower onset (several hours for thawing and infusion)
Less effective INR correction than PCC
Volume overload risk
Transfusion-related complications

Evidence: The INCH trial demonstrated 4F-PCC achieved hemostatic efficacy in 72% vs 65% with FFP, with faster INR correction and lower volume administration[6].

Hack #3: The "PCC Plus" Protocol - For life-threatening bleeding with INR >6, combine 4F-PCC (50 units/kg) + vitamin K 10 mg IV + tranexamic acid 1g IV. This provides immediate reversal, sustained effect, and antifibrinolytic coverage.

DOAC Reversal

DOACs include direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban). Management varies by agent and bleeding severity.

Dabigatran (Direct Thrombin Inhibitor)

Idarucizumab (Praxbind) - Specific Reversal Agent:

Monoclonal antibody fragment that binds dabigatran
Dose: 5 g IV (two 2.5 g doses given 15 minutes apart, or as single 5 g bolus)
Onset: Immediate (within minutes)
Duration: Sustained reversal
Extremely effective: >90% reversal within 4 hours[7]

When Idarucizumab Unavailable:

4F-PCC: 50 units/kg (off-label, limited evidence)
Hemodialysis: Removes 50-60% of dabigatran in 2-3 hours (dabigatran is 65% renally excreted and dialyzable)
Activated PCC (FEIBA): 50 units/kg (higher thrombotic risk)

Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban)

Andexanet Alfa (Andexxa) - Specific Reversal Agent:

Modified recombinant factor Xa that acts as decoy, binding factor Xa inhibitors
Dosing (based on drug, dose, and timing):
- Low dose regimen: 400 mg IV bolus at 30 mg/min, followed by 4 mg/min infusion for 120 minutes
- High dose regimen: 800 mg IV bolus at 30 mg/min, followed by 8 mg/min infusion for 120 minutes
Use high dose for: rivaroxaban ≥10 mg, apixaban ≥5 mg, or edoxaban taken within <8 hours
Use low dose for: apixaban ≤2.5 mg, rivaroxaban ≤10 mg, or edoxaban taken >8 hours ago
Excellent efficacy: 82% hemostatic efficacy in ANNEXA-4 trial[8]

Oyster #3: The Andexanet "Rebound" Phenomenon - Anti-Xa activity may increase 2-6 hours after andexanet infusion ends due to redistribution. Consider redosing if bleeding recurs. Infusion duration matters—don't just give the bolus.

When Andexanet Unavailable (4F-PCC as Alternative):

Dose: 50 units/kg (some protocols use 2,000 units fixed dose)
Less effective than andexanet (indirect mechanism)
Onset: 15-30 minutes
Meta-analyses show clinical hemostasis in 60-75% of cases[9]
Thrombotic risk: 5-8%

Activated PCC (FEIBA):

50 units/kg (maximum 5,000 units)
Contains activated factor VII
Higher thrombotic risk (8-10%)
Reserve for life-threatening bleeding when andexanet and 4F-PCC fail

Pearl #4: The "Time-Drug-Dose" Trifecta - DOAC reversal urgency depends on three factors: time since last dose (half-lives: apixaban 12h, rivaroxaban 7-11h, edoxaban 10-14h), drug-specific dose, and renal function. If >24 hours since last dose with normal renal function, observation may suffice for minor bleeding.

General Principles for All Anticoagulant Reversals

Discontinue the anticoagulant immediately
Activate massive transfusion protocol if indicated
Maintain normothermia (>36°C), normal pH (>7.2), ionized calcium (>1.1 mmol/L)
Consider tranexamic acid: 1 g IV bolus (if no contraindication to antifibrinolytics)
Target hemoglobin 7-9 g/dL (restrictive strategy unless active hemorrhage)
Surgical hemostasis takes priority - reversal supports but doesn't replace source control

Hack #4: The "Reversal Checklist" - For major bleeding on any anticoagulant:

[ ] Specific reversal agent (if available)
[ ] 4F-PCC (if no specific agent)
[ ] Vitamin K 10 mg IV (even for DOACs—may have subclinical vitamin K deficiency)
[ ] Tranexamic acid 1 g IV
[ ] Correct hypothermia, acidosis, hypocalcemia
[ ] Activate MTP if hemodynamically unstable

Managing Coagulopathies: Focus on Liver Disease

Pathophysiology of Coagulopathy in Liver Disease

Liver disease produces a complex "rebalanced" hemostatic state with simultaneous pro- and anti-hemorrhagic abnormalities[10]:

Pro-Hemorrhagic Factors:

Decreased synthesis of procoagulant factors (all except VIII and vWF)
Thrombocytopenia (splenic sequestration, decreased thrombopoietin)
Platelet dysfunction
Decreased fibrinogen (quantity and quality)
Hyperfibrinolysis (decreased clearance of tPA)

Pro-Thrombotic Factors:

Decreased synthesis of anticoagulants (protein C, protein S, antithrombin)
Elevated factor VIII and von Willebrand factor
Decreased clearance of activated factors

Oyster #4: The "INR Illusion" - Elevated INR in liver disease doesn't predict bleeding risk and poorly guides transfusion decisions. Patients with cirrhosis and INR of 2.5 have similar or lower bleeding rates than those with normal INR due to rebalanced hemostasis. Treat the patient, not the INR.

Assessment of Bleeding Risk in Liver Disease

Traditional tests (PT/INR, aPTT) only measure procoagulant activity and ignore anticoagulant deficiency. VET provides more comprehensive assessment:

Thrombin generation assays show normal or increased thrombin in compensated cirrhosis
TEG/ROTEM often normal or hypercoagulable despite prolonged INR

Clinical Risk Stratification:

Low risk: Compensated cirrhosis, minor procedures
Intermediate risk: Decompensated cirrhosis, moderate procedures
High risk: Acute-on-chronic liver failure, active bleeding, portal hypertension procedures

Management Strategies

For Active Bleeding

1. Resuscitation and General Measures:

Restrictive transfusion strategy: target Hb 7-8 g/dL (over-transfusion worsens portal pressure)
Correct thrombocytopenia: target >50,000/μL
Maintain fibrinogen >150 mg/dL
Avoid FFP unless VET-guided or life-threatening bleeding

2. Platelet Management:

Threshold: <50,000/μL for major bleeding; <20,000/μL for minor
Thrombopoietin receptor agonists (avatrombopag, lusutrombopag): For elective procedures, start 5-8 days prior (not for acute bleeding)
Platelet transfusion: 1 unit increases count by ~5,000-10,000/μL
DDAVP (desmopressin): 0.3 μg/kg IV for platelet dysfunction (releases vWF and factor VIII stores)

3. Coagulation Factor Replacement:

FFP:

Dose: 10-20 mL/kg
Problems: Volume overload, minimal INR improvement, worsens ascites
Use sparingly, only for severe bleeding unresponsive to other measures

Cryoprecipitate:

For fibrinogen <150 mg/dL
Dose: 1 unit/10 kg (typically 10 units)
Each unit provides ~250 mg fibrinogen
Preferred over FFP for isolated fibrinogen deficiency

Prothrombin Complex Concentrate:

Emerging role in liver disease
Provides concentrated factors without volume
Dose: 25-50 units/kg
Limited evidence but increasing use
Theoretical thrombotic risk (monitor closely)

Pearl #5: The "Fibrinogen-First" Strategy - In liver disease bleeding, fibrinogen is often the most critical deficiency. Check fibrinogen first, replace with cryoprecipitate to >150-200 mg/dL before considering other products.

4. Antifibrinolytic Therapy:

Tranexamic Acid:

Dose: 1 g IV loading, then 1 g over 8 hours or 1 g q8h
Particularly useful in liver disease with hyperfibrinolysis
Contraindications: Upper urinary tract bleeding, DIC, thrombotic risk
HALT-IT trial showed no mortality benefit in GI bleeding but trend toward benefit in cirrhotic subgroup[11]

Aminocaproic Acid:

Alternative to tranexamic acid
Dose: 5 g IV loading, then 1 g/hour

5. Vitamin K:

10 mg IV daily for 3 days
Many cirrhotic patients have vitamin K deficiency
May modestly improve INR in 24-48 hours
Low risk, reasonable to give empirically

Hack #5: The "Cirrhotic Bleeding Bundle" - For major bleeding in cirrhosis:

Cryoprecipitate to fibrinogen >150 mg/dL (FIRST)
Platelet transfusion if <50,000/μL
Tranexamic acid 1 g IV
Vitamin K 10 mg IV
DDAVP 0.3 μg/kg IV (for platelet dysfunction)
Avoid FFP unless VET-guided or profound coagulopathy with ongoing bleeding
PCC consideration if above measures fail

For Procedural Prophylaxis

Risk-Stratified Approach:

Low-Risk Procedures (central line, paracentesis, thoracentesis):

No prophylaxis needed regardless of INR or platelet count
Data show safety with INR <3 and platelets >20,000/μL[12]

Intermediate-Risk Procedures (endoscopy with intervention, dental):

Target platelets >30,000-50,000/μL
No routine FFP
Consider tranexamic acid pre-procedure

High-Risk Procedures (major surgery, liver biopsy, variceal banding):

Target platelets >50,000/μL
Fibrinogen >150 mg/dL
Consider VET-guided therapy
PCC may be preferable to FFP (less volume)

Pearl #6: The "Minimize Plasma" Philosophy - In liver disease, FFP should be last resort, not first line. Volume overload worsens ascites, portal hypertension, and cardiac stress. Use targeted factor replacement when possible.

Special Scenarios in Liver Disease

Acute Variceal Hemorrhage:

Octreotide: 50 μg bolus, then 50 μg/hour infusion (reduces portal pressure)
Antibiotic prophylaxis: Ceftriaxone 1 g daily (reduces infection, rebleeding, mortality)
Early endoscopy within 12 hours
Avoid over-resuscitation (target MAP 65 mmHg, avoid Hb >9 g/dL)
Tranexamic acid role unclear but consider

Acute-on-Chronic Liver Failure (ACLF):

More severe coagulopathy with higher bleeding risk
Multiorgan dysfunction complicates management
May require more aggressive factor replacement
Consider early ICU involvement

Oyster #5: The "Rebound Thrombosis" Risk - After surviving major bleeding, cirrhotic patients have paradoxically high thrombotic risk (portal vein thrombosis, DVT). Once hemostasis achieved, reassess thromboprophylaxis within 24-48 hours if no ongoing bleeding.

Clinical Pearls Summary

Rule of Halves: 50% surgical, 25% coagulopathic, 25% mixed
VET-Guided Therapy: Reduces transfusions by 20-40%
Correct and Reassess: Fix coagulopathy, then re-evaluate for surgical cause
Time-Drug-Dose Trifecta: DOAC reversal urgency depends on timing, dose, renal function
Fibrinogen-First Strategy: Priority replacement in liver disease bleeding
Minimize Plasma Philosophy: Avoid FFP in cirrhosis when possible

Hacks for Clinical Practice

Three-Site Rule: Bleeding from ≥3 sites = coagulopathy
Platelet Function "Clock": Know antiplatelet duration
PCC Plus Protocol: 4F-PCC + vitamin K + TXA for severe warfarin bleeding
Reversal Checklist: Systematic approach to anticoagulation reversal
Cirrhotic Bleeding Bundle: Structured 7-step approach

Conclusion

Perioperative bleeding management requires systematic evaluation, targeted diagnostics, and evidence-based interventions. The critical care physician must distinguish surgical from medical causes, rapidly reverse anticoagulation when appropriate, and understand the unique hemostatic challenges in liver disease. Viscoelastic testing, specific reversal agents, and avoidance of unnecessary blood products represent key advances. As anticoagulant use expands and patient populations grow more complex, mastery of these principles becomes essential for optimizing outcomes in the perioperative period.

References

Karkouti K, et al. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation. 2008;117(4):478-484.
Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol. 2014;89(2):228-232.
Görlinger K, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery. Anesthesiology. 2011;115(6):1179-1191.
Veigas PV, et al. A systematic review on the rotational thromboelastometry (ROTEM®) values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients. Scand J Trauma Resusc Emerg Med. 2016;24:114.
Paniccia R, et al. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133-148.
Sarode R, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243.
Pollack CV Jr, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431-441.
Connolly SJ, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326-1335.
Gómez-Outes A, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol. 2021;77(16):2987-3001.
Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.
HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10241):1927-1936.
Patel IJ, et al. Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions. J Vasc Interv Radiol. 2019;30(8):1171-1197.

Keywords: Perioperative bleeding, anticoagulation reversal, coagulopathy, prothrombin complex concentrate, andexanet alfa, liver disease, viscoelastic testing, tranexamic acid, hemostasis

Perioperative Management of Surgical Patients with Solid Organ Transplants: A Critical Care Perspective

Perioperative Management of Surgical Patients with Solid Organ Transplants: A Critical Care Perspective

Dr Neeraj Manikath , claude ai

Abstract

Solid organ transplant recipients present unique challenges in the perioperative period, requiring meticulous attention to immunosuppression management, infection risk stratification, and complex drug interactions. This review synthesizes current evidence and clinical pearls for intensivists and anesthesiologists managing these high-risk patients during non-transplant surgical procedures.

Introduction

Over 40,000 solid organ transplants are performed annually in the United States, with kidney transplants comprising approximately 60% of cases, followed by liver, heart, lung, and combined organ transplants. The growing transplant population, combined with improved long-term survival, means that 1-2% of transplant recipients require non-transplant surgery annually. These patients pose significant perioperative challenges due to chronic immunosuppression, altered physiology, comorbid conditions, and the ever-present risk of graft rejection versus infection.

Clinical Pearl: The transplanted organ is denervated and lacks normal physiologic feedback mechanisms. A transplanted heart cannot mount a tachycardic response to hypovolemia, while a transplanted liver may not exhibit typical signs of rejection.

Perioperative Management of Immunosuppressants

Fundamental Principles

The cornerstone of transplant patient management is maintaining therapeutic immunosuppression while minimizing surgical complications. The typical regimen includes a calcineurin inhibitor (CNI) such as tacrolimus or cyclosporine, an antimetabolite (mycophenolate mofetil or azathioprine), and corticosteroids. Many patients also receive mammalian target of rapamycin (mTOR) inhibitors like sirolimus or everolimus.

The Golden Rule: Never discontinue immunosuppression perioperatively unless explicitly directed by the transplant team. Even brief interruptions can trigger acute rejection, with potentially catastrophic consequences.

Specific Drug Management

Calcineurin Inhibitors (Tacrolimus/Cyclosporine)

These agents form the backbone of maintenance immunosuppression but have narrow therapeutic windows. Tacrolimus target trough levels typically range from 5-15 ng/mL depending on time post-transplant and organ type, while cyclosporine targets are 100-400 ng/mL.

Perioperative Strategy:

Continue oral formulations until 2-4 hours preoperatively if NPO status permits
For prolonged NPO periods, convert to intravenous administration at 1/3 to 1/4 of the oral dose
Tacrolimus IV: 0.01-0.05 mg/kg/day as continuous infusion
Cyclosporine IV: 1/3 of oral dose, divided into continuous infusion

Hack: For patients on morning-of-surgery NPO restrictions, administer the morning dose of tacrolimus with a small sip of water. The absorption is rapid, and the risk of aspiration with 30 mL of water is negligible compared to the rejection risk.

Mycophenolate Mofetil (MMF)/Mycophenolic Acid

These antimetabolites inhibit inosine monophosphate dehydrogenase, blocking lymphocyte proliferation. Standard dosing is 1-2 grams daily in divided doses.

Perioperative Controversy: Some advocate holding MMF 24-48 hours preoperatively for procedures with high infection or wound dehiscence risk (bowel surgery, complex wound closures). However, this practice lacks robust evidence and increases rejection risk.

Evidence-Based Approach:

Continue MMF for most elective procedures
Consider holding only for high-risk GI surgery or in patients with severe neutropenia (ANC <500/μL)
Resume as soon as enteral intake tolerated, typically within 24-48 hours
No IV formulation widely available; use NG tube if necessary

mTOR Inhibitors (Sirolimus/Everolimus)

These agents impair wound healing and increase anastomotic complications through anti-proliferative effects on fibroblasts and endothelial cells. Meta-analyses demonstrate 2-3 fold increased risk of wound dehiscence, lymphocele formation, and impaired anastomotic healing.

Perioperative Management:

Discontinue 1-2 weeks before elective surgery with high wound complication risk
May continue for minor procedures (hernia repair, endoscopy)
Resume 2 weeks postoperatively once wound healing established
Oyster: The long half-life (60-80 hours for sirolimus) means effects persist for weeks after discontinuation. Plan accordingly.

Corticosteroids

All transplant recipients receive maintenance prednisone (typically 5-10 mg daily) or equivalent. Perioperative stress-dose steroids remain controversial but are generally recommended for patients on >5 mg daily prednisone for >3 weeks.

Stress Dosing Protocol:

Minor surgery (hernia, endoscopy): Continue maintenance dose
Moderate surgery (cholecystectomy, joint replacement): Hydrocortisone 50 mg IV q8h for 24 hours
Major surgery (bowel resection, vascular): Hydrocortisone 100 mg IV q8h, taper over 2-3 days

Pearl: Adrenal insufficiency in transplant patients is multifactorial—chronic steroid suppression, CNI effects on cortisol metabolism, and critical illness all contribute. When in doubt, provide stress coverage.

Monitoring and Target Levels

Therapeutic drug monitoring is essential perioperatively:

Check CNI trough levels daily during ICU stay
Monitor for nephrotoxicity (creatinine, electrolytes)
CBC to assess for bone marrow suppression
Coordinate with transplant pharmacy for dose adjustments

Hack: Many transplant centers use trough-to-dose ratios to guide dosing adjustments rather than population pharmacokinetics, improving precision.

Assessing Infection Risk in Immunocompromised Hosts

Risk Stratification Framework

Infection remains the leading cause of morbidity and mortality in transplant recipients, accounting for 20-30% of deaths. Risk assessment requires understanding the "transplant timeline" and individual patient factors.

The Transplant Timeline:

0-1 month: Nosocomial and surgical site infections predominate
1-6 months: Opportunistic infections peak (CMV, Pneumocystis, fungal)
>6 months: Community-acquired infections plus late viral reactivations

Pearl: A patient 3 years post-transplant on stable low-dose immunosuppression has vastly different infection risk than a patient 2 months post-transplant on high-dose induction therapy.

Net State of Immunosuppression

This concept, introduced by Fishman and Rubin, integrates multiple factors:

Dose, duration, and sequence of immunosuppressive drugs
Neutropenia and lymphopenia (absolute counts matter)
Mucosal barrier integrity (indwelling lines, surgical wounds)
Viral infections (CMV, EBV amplify immunosuppression)
Metabolic factors (diabetes, uremia, malnutrition)
Recipient-specific factors (age, previous infections, vaccination status)

Risk Calculator Approach:

Low risk: >1 year post-transplant, stable function, maintenance immunosuppression
Moderate risk: 3-12 months post-transplant, recent rejection treatment
High risk: <3 months post-transplant, recent ATG/alemtuzumab, active CMV viremia, or multi-organ transplant

Specific Pathogen Considerations

Cytomegalovirus (CMV)

CMV serostatus matching (donor/recipient) determines prophylaxis strategies:

D+/R-: Highest risk (30-70% without prophylaxis)
R+: Moderate risk (20-30%)
D-/R-: Lowest risk (<5%)

Perioperative Management:

Continue valganciclovir prophylaxis perioperatively
Monitor CMV PCR weekly in high-risk patients during ICU stays
Oyster: CMV disease can present as isolated fever without end-organ manifestations in the early stages. Maintain high suspicion.

Pneumocystis jirovecii

Universal prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) has reduced PCP incidence to <1%. Continue through the perioperative period.

Alternatives (if TMP-SMX intolerant):

Dapsone 100 mg daily (check G6PD first)
Atovaquone 1500 mg daily (expensive, GI side effects)
Inhaled pentamidine 300 mg monthly (less effective)

Fungal Infections

Invasive aspergillosis and candidiasis risk peaks in the early post-transplant period and during high-dose immunosuppression.

Risk Factors:

Prolonged ICU stay
Broad-spectrum antibiotics
Renal replacement therapy
TPN with central lines
Re-transplantation

Hack: Serum beta-D-glucan and galactomannan testing provides early detection of invasive fungal infections before clinical manifestations. Consider screening high-risk patients postoperatively.

Prophylaxis Strategies

Antibiotic Prophylaxis: Standard surgical prophylaxis applies, but consider:

Extended spectrum coverage for high-risk GI or biliary surgery
Anti-pseudomonal coverage for lung transplant recipients
MRSA coverage based on colonization status

Pearl: Transplant recipients should receive antimicrobial prophylaxis for dental procedures regardless of cardiac risk factors, as endocarditis risk is elevated.

Antiviral Prophylaxis:

Acyclovir/valacyclovir for HSV prophylaxis (renal/liver)
Valganciclovir for CMV prophylaxis (continue perioperatively)

Vaccination Considerations

Oyster: Live vaccines are absolutely contraindicated in solid organ transplant recipients. Inactivated vaccines have reduced immunogenicity but should be administered when appropriate.

Drug Interactions Between Anesthesia and Transplant Medications

Calcineurin Inhibitors: The Interaction Hub

Both tacrolimus and cyclosporine are metabolized via hepatic CYP3A4 and are substrates for P-glycoprotein. This creates numerous potential interactions with anesthetic agents.

CYP3A4 Inhibitors (Increase CNI Levels):

Azole antifungals (fluconazole, voriconazole, itraconazole): 2-5 fold increase
Macrolide antibiotics (erythromycin, clarithromycin): 2-3 fold increase
Calcium channel blockers (diltiazem, verapamil): 1.5-2 fold increase
Protease inhibitors
Grapefruit juice (yes, this still matters)

CYP3A4 Inducers (Decrease CNI Levels):

Anticonvulsants (phenytoin, phenobarbital, carbamazepine)
Rifampin: profound decrease (50-80%)
St. John's Wort

Anesthetic-Specific Interactions:

Propofol: No significant effect on CNI metabolism, but profound vasodilation may unmask relative hypovolemia in patients with autonomic dysfunction post-transplant.

Volatile Anesthetics: Minimal direct interaction with immunosuppressants. Isoflurane and sevoflurane are hepatically metabolized but don't significantly alter CYP3A4 activity acutely.

Hack: Desflurane has the lowest hepatic metabolism (<0.02%) and may be preferred in liver transplant recipients with marginal graft function.

Benzodiazepines: Midazolam is a CYP3A4 substrate. Patients on CNIs may have prolonged sedation. Start with 50% usual dose and titrate carefully.

Opioids: Fentanyl and alfentanil are CYP3A4 substrates with potential for prolonged effects. Remifentanil (esterase metabolism) avoids this issue.

Neuromuscular Blockers: Rocuronium and vecuronium are hepatically eliminated; effects may be prolonged in liver transplant recipients. Sugammadex provides reliable reversal regardless of hepatic function.

Pearl: Atracurium and cisatracurium undergo Hofmann elimination (spontaneous degradation) and are ideal choices in patients with hepatic or renal dysfunction.

Specific Transplant-Anesthesia Considerations

Kidney Transplant Recipients:

Avoid nephrotoxic agents (NSAIDs, aminoglycosides)
Maintain MAP >65 mmHg to preserve graft perfusion
Monitor urine output religiously
Oyster: Transplanted kidneys are denervated and maximally vasodilated at baseline. They cannot autoregulate in response to hypotension.

Liver Transplant Recipients:

Altered drug metabolism unpredictable
Coagulopathy may persist (check INR/TEG)
Encephalopathy risk with sedatives
Hack: Using multimodal analgesia (acetaminophen, regional techniques) minimizes opioid requirements and preserves mental status.

Heart Transplant Recipients:

Denervated heart: no vagal tone, fixed resting HR ~90-110 bpm
Cannot increase HR in response to decreased preload
Direct-acting agents required (isoproterenol, epinephrine)
Atropine ineffective; glycopyrrolate preferred for bradycardia
Critical Pearl: Maintain strict preload; these patients are exquisitely sensitive to hypovolemia and cannot compensate with tachycardia.

Lung Transplant Recipients:

Loss of cough reflex below anastomosis
Bronchial hyperreactivity common
Avoid histamine-releasing drugs (morphine, atracurium)
Lung-protective ventilation essential (TV 6-8 mL/kg IBW)

Corticosteroid Interactions

Chronic corticosteroid use alters drug metabolism and physiology:

Increased gastric acid production
Glucose intolerance
Electrolyte disturbances (hypokalemia, metabolic alkalosis)
Mood alterations

Anesthetic Implications:

Stress-dose steroids as discussed above
Aggressive glycemic control (target <180 mg/dL)
Monitor electrolytes closely

Sirolimus/Everolimus Considerations

Beyond wound healing concerns:

Impaired platelet function (verify platelet aggregation studies if available)
Hyperlipidemia (common)
Interstitial pneumonitis (rare but consider if unexplained hypoxemia)
Drug interactions similar to CNIs (CYP3A4 substrate)

Practical Drug Interaction Management

Preoperative Planning:

Obtain complete medication list including over-the-counter and herbal supplements
Verify most recent CNI trough level
Review planned antibiotic prophylaxis with transplant pharmacy
Anticipate need for alternative immunosuppression routes

Intraoperative Monitoring:

Invasive arterial monitoring for major cases (beat-to-beat BP crucial)
Consider TEG/ROTEM for liver transplant recipients
Core temperature monitoring (immunosuppressants impair thermoregulation)

Postoperative Drug Management:

Resume immunosuppression as soon as feasible
Check CNI trough on POD #1 and adjust for surgical stress, drug interactions
Monitor for signs of rejection (fever, graft dysfunction, constitutional symptoms)
Coordinate with transplant team for any adjustment in immunosuppression

Hack: Create a standardized "Transplant Perioperative Order Set" in your EMR that automatically prompts stress-dose steroids, CNI level monitoring, and antimicrobial prophylaxis. This reduces errors and improves compliance.

Conclusion

Surgical patients with solid organ transplants require meticulous perioperative management integrating principles of immunosuppression maintenance, infection risk stratification, and awareness of complex drug interactions. The intensivist must balance the competing risks of under-immunosuppression (leading to rejection) against over-immunosuppression (increasing infection risk). Success depends on multidisciplinary collaboration with transplant teams, infectious disease specialists, and transplant pharmacists. With careful attention to the principles outlined in this review, excellent outcomes can be achieved even in high-risk transplant recipients undergoing complex surgical procedures.

Key Takeaways ("Pearls and Oysters")

Pearls:

Never stop immunosuppression perioperatively without transplant team approval
Transplanted organs are denervated—normal physiologic responses are absent
The "net state of immunosuppression" determines infection risk, not just drug doses
Stress-dose steroids for patients on >5 mg prednisone daily undergoing moderate-major surgery
CNIs are CYP3A4 substrates—anticipate interactions with azoles, macrolides, and calcium channel blockers

Oysters (Hidden Traps):

mTOR inhibitors impair wound healing for weeks after discontinuation due to long half-lives
CMV disease can present as isolated fever without obvious end-organ involvement
Atropine doesn't work in heart transplant recipients—use direct-acting agents
Transplanted kidneys cannot autoregulate during hypotension—MAP goals are critical
Midazolam effects prolonged in patients on CNIs—start with 50% dose

References

Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601-2614.
Rubin RH. The net state of immunosuppression: a framework for rethinking opportunistic infections. Curr Opin Infect Dis. 2007;20(4):395-400.
Cannesson M, Kain Z. Anesthetic management of patients after solid organ transplantation. Anesthesiol Clin. 2013;31(4):705-721.
Kang E, Kim Y, Park S. Perioperative management of immunosuppressive drugs in solid organ transplant recipients. Korean J Anesthesiol. 2019;72(4):317-327.
Axelrod DA, Lentine KL. Critical reviews in perioperative care of transplant patients. Anesthesiol Clin. 2017;35(3):433-451.
Singh N, Limaye AP, Forrest G, et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol. 2006;44(5):445-449.
Kostopanagiotou G, Smyrniotis V, Arkadopoulos N, et al. Anesthetic and perioperative management of adult transplant recipients in nontransplant surgery. Anesth Analg. 1999;89(3):613-622.
Blasco LM, Paramesh A, Bozorgzadeh A, et al. Perioperative complications in solid organ transplantation. Curr Opin Organ Transplant. 2009;14(3):303-309.
Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77(10):1555-1561.
Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900-931.

Word count: Approximately 2,000 words

Disclosure: This review reflects current evidence-based practices; however, institutional protocols may vary. Always consult with the patient's transplant team for specific management decisions.

Perioperative Management of Rheumatologic Conditions: A Critical Care Perspective

A Comprehensive Review for Critical Care Trainees

Dr Neeraj Manikath , claude.ai

Introduction

The perioperative management of patients with rheumatologic conditions represents a delicate balance between minimizing disease flare risk and reducing perioperative complications. With the expanding arsenal of biologic disease-modifying antirheumatic drugs (DMARDs) and the complex interplay of immunosuppression, infection risk, and surgical stress, intensivists must navigate multiple competing priorities. This review addresses three critical domains essential for optimizing outcomes in this vulnerable population.

Timing of Biologic DMARDs and Immunosuppressants

The Pharmacokinetic Approach

The modern paradigm for timing biologic DMARD withdrawal centers on achieving drug washout equivalent to one half-life before surgery, thereby minimizing circulating drug levels while avoiding prolonged discontinuation that precipitates disease flare.

TNF-α Inhibitors:

Infliximab (half-life 7-12 days): Discontinue 4-6 weeks preoperatively[1]
Adalimumab (half-life 10-20 days): Discontinue 2-4 weeks preoperatively[2]
Etanercept (half-life 3-5 days): Discontinue 1-2 weeks preoperatively[1]
Certolizumab pegol (half-life 14 days): Discontinue 2-4 weeks preoperatively
Golimumab (half-life 14 days): Discontinue 2-4 weeks preoperatively

Pearl: Certolizumab, lacking an Fc region, does not cross the placenta and may be preferred in pregnant patients requiring perioperative management.

IL-6 Inhibitors:

Tocilizumab IV (half-life 11-13 days): Discontinue 4 weeks preoperatively[3]
Tocilizumab SC (half-life similar): Discontinue 3-4 weeks preoperatively
Sarilumab (half-life 8-22 days): Discontinue 3-4 weeks preoperatively

B-Cell Depleting Agents:

Rituximab (half-life 18-32 days): Ideally schedule surgery when B-cell reconstitution begins (typically 6-9 months post-infusion)[4]
Effect persists far beyond drug clearance due to sustained B-cell depletion

Oyster: The 2017 ACR/AAHKS guidelines recommend continuing rituximab and abatacept through elective arthroplasty, challenging conventional wisdom. However, this applies specifically to elective orthopedic procedures in carefully selected patients[5].

T-Cell Costimulation Inhibitor:

Abatacept IV (half-life 8-25 days): Discontinue 4 weeks preoperatively
Abatacept SC (half-life 14 days): Discontinue 1-2 weeks preoperatively[2]

IL-17 and IL-23 Inhibitors:

Secukinumab (half-life 27 days): Discontinue 3-4 weeks preoperatively
Ixekizumab (half-life 13 days): Discontinue 2-3 weeks preoperatively
Ustekinumab (half-life 19-28 days): Discontinue 4-6 weeks preoperatively
Guselkumab (half-life 15-18 days): Discontinue 3-4 weeks preoperatively

JAK Inhibitors: The Unique Challenge

JAK inhibitors (tofacitinib, baricitinib, upadacitinib) present distinct perioperative considerations:

Short half-lives (3-12 hours) allow rapid washout
Discontinue 3-7 days preoperatively[6]
Black box warnings for thrombosis and infection necessitate careful risk stratification
Emerging data suggest increased venous thromboembolism risk in elderly patients with cardiovascular risk factors

Hack: For urgent surgery, JAK inhibitors' rapid clearance is advantageous—a 24-48 hour delay may suffice for adequate washout in emergency settings.

Conventional Synthetic DMARDs

Methotrexate: Controversy resolved: Continue methotrexate perioperatively[5,7]. The landmark PEXIVAS and multiple cohort studies demonstrate no increased infection risk and reduced flare rates with continuation.

Exception: Major surgery with anticipated prolonged NPO status or severe renal impairment

Leflunomide:

Extremely long half-life (14-18 days for active metabolite)
Discontinue 4-6 weeks preoperatively for major surgery[8]
Consider cholestyramine washout for urgent cases (8g TID for 11 days reduces levels by 40%)

Hydroxychloroquine:

Continue perioperatively—no immunosuppressive effect at therapeutic doses[5]
Provides disease control without infection risk

Sulfasalazine:

Continue perioperatively for most procedures
Consider holding for bowel surgery due to potential anastomotic healing concerns (limited evidence)

Glucocorticoids

Never discontinue abruptly—continue at maintenance dose
Address adrenal insufficiency risk (see next section)
Doses >10mg/day prednisone equivalent: consider wound healing and infection implications

Pearl: The infection risk from glucocorticoids is dose-dependent and duration-dependent. Current prednisone >20mg/day or cumulative exposure matters more than biologic use for infection risk[9].

Postoperative Resumption

General Principle: Resume therapy when:

Adequate wound healing established
No signs of infection
Patient tolerating oral intake (if applicable)
Typically 14 days for major surgery, 7 days for minor procedures[2]

Hack: For patients at high flare risk (active lupus nephritis, vasculitis), consider bridging with low-dose prednisone rather than prolonged DMARD discontinuation.

Managing Adrenal Insufficiency in Chronic Steroid Users

Understanding HPA Axis Suppression

Hypothalamic-pituitary-adrenal (HPA) axis suppression risk correlates with:

Dose: >5mg prednisone daily for >3 weeks
Duration: Risk increases substantially after 3 months
Timing: Evening doses suppress more than morning doses
Formulation: Systemic > inhaled/topical (though high-dose inhaled steroids can suppress)

Oyster: Not all patients on chronic steroids are adrenally insufficient. Studies show only 50-60% of patients on chronic prednisone ≥5mg have HPA suppression[10]. However, testing is impractical perioperatively—empiric coverage is standard.

Risk Stratification Framework

High Risk for Perioperative Adrenal Crisis:

Prednisone ≥20mg daily for >3 weeks
Any dose of systemic glucocorticoids for >3 months with Cushingoid features
Previous adrenal insufficiency diagnosis
Major surgery with significant physiologic stress

Moderate Risk:

Prednisone 5-20mg daily for >3 weeks
Intermediate-risk surgery (orthopedic, vascular)

Low Risk:

Prednisone <5mg daily
Minor surgery (cataract, dental)
Topical/inhaled steroids only (unless very high dose)

Perioperative Steroid Supplementation Protocols

The traditional "stress dose steroid" teaching has evolved toward more conservative approaches based on physiologic cortisol response to surgical stress[11].

For Minor Surgery (local anesthesia, minimal stress):

Continue home dose
No supplementation needed
Examples: cataract surgery, dental procedures, skin biopsies

For Moderate Surgery (peripheral orthopedic, open cholecystectomy):

Classic approach: Hydrocortisone 50mg IV at induction, then 25mg IV q8h × 24-48 hours
Modern conservative approach: Continue home dose + hydrocortisone 25-50mg IV at induction, then resume home dose[12]

For Major Surgery (cardiothoracic, major abdominal, vascular):

Hydrocortisone 100mg IV at induction
Followed by 50mg IV q8h or continuous infusion at 200mg/24h
Taper over 2-3 days as patient stabilizes
Resume home dose once tolerating oral intake

Pearl: Hydrocortisone provides both glucocorticoid and mineralocorticoid activity, making it ideal for acute stress coverage. If unavailable, methylprednisolone 40mg IV = hydrocortisone 100mg, but add fludrocortisone 0.1mg daily for mineralocorticoid support.

The Septic Shock Conundrum

Patients with baseline adrenal insufficiency risk presenting differently in septic shock:

May have relative adrenal insufficiency superimposed on chronic suppression
Consider hydrocortisone 50mg IV q6h or 200mg/24h infusion per Surviving Sepsis guidelines[13]
This dose provides both stress coverage and septic shock management
Critical: Don't delay recognition—unexplained hypotension refractory to fluids and vasopressors despite adequate resuscitation suggests adrenal crisis

Hack: Random cortisol <10 μg/dL during shock suggests insufficiency, but never delay treatment for testing. In known chronic steroid users with refractory shock, empiric stress-dose steroids are lifesaving.

Monitoring and Complications

Clinical Monitoring:

Vital signs, especially blood pressure
Electrolytes (hyponatremia, hyperkalemia suggest insufficiency)
Blood glucose (stress steroids cause hyperglycemia)
Signs of infection (steroids mask fever and inflammatory response)

Red Flags for Adrenal Crisis:

Hypotension unresponsive to fluid resuscitation
Altered mental status
Fever, nausea, vomiting, abdominal pain
Hyponatremia, hyperkalemia, hypoglycemia

Weaning Strategy

For patients requiring stress-dose coverage:

Rapid taper once hemodynamically stable and tolerating oral intake
Day 1 post-stability: Reduce to 50mg q8h (or equivalent)
Day 2: Reduce to 25mg q8h or switch to oral prednisone 20-30mg
Day 3: Transition to home dose

Oyster: HPA axis recovery is unpredictable. Some patients require months to recover function after stopping chronic steroids. This doesn't affect acute perioperative management but matters for long-term planning.

Assessing Infection Risk in Immunocompromised Rheumatology Patients

The Multifactorial Nature of Infection Risk

Infection risk in rheumatology patients results from:

Underlying disease activity (lupus, vasculitis themselves impair immunity)
Immunosuppressive medications
Structural damage (bronchiectasis, skin ulcers)
Comorbidities (diabetes, chronic kidney disease, lung disease)
Surgical factors (procedure type, duration, implanted devices)

Risk Stratification by Medication Class

Highest Risk (Relative Risk 2-5× baseline):

Rituximab: Profound hypogammaglobulinemia, encapsulated bacterial infections, PJP risk[14]
Cyclophosphamide: Severe leukopenia, PJP, fungal infections
High-dose glucocorticoids (>20mg/day): Bacterial, fungal, opportunistic infections[9]
JAK inhibitors: Herpes zoster (10-15% annually), tuberculosis reactivation[15]

Moderate Risk (Relative Risk 1.5-2× baseline):

TNF-α inhibitors: Tuberculosis reactivation, fungal infections (especially histoplasmosis, coccidioidomycosis)[16]
Tocilizumab: Bacterial infections, GI perforation risk
Mycophenolate mofetil: Herpes virus infections, PJP
Azathioprine: Modest immunosuppression

Lower Risk (Relative Risk <1.5× baseline):

Methotrexate (monotherapy): Minimal infection risk at standard doses[7]
Hydroxychloroquine: No immunosuppression
Sulfasalazine: Minimal risk
Abatacept, IL-17/IL-23 inhibitors: Relatively safer profiles

Pearl: Combination therapy dramatically increases risk. Prednisone + biologic + conventional DMARD creates additive/synergistic infection susceptibility.

Specific Pathogen Considerations

Tuberculosis Screening:

Mandatory before TNF-α inhibitors, JAK inhibitors, rituximab[17]
Tuberculin skin test (TST) or interferon-gamma release assay (IGRA)
Chest radiograph
Consider IGRA over TST in BCG-vaccinated patients
Treat latent TB before immunosuppression (isoniazid 300mg daily × 9 months or rifampin 600mg daily × 4 months)

Hack: In urgent surgical situations where TB screening was never completed, obtain baseline testing and start prophylaxis empirically if high-risk epidemiology or chest X-ray abnormalities exist. Don't delay necessary surgery for TB workup completion.

Pneumocystis jirovecii Pneumonia (PJP):

Prophylaxis indicated when: Prednisone ≥20mg × >1 month + another immunosuppressant, or cyclophosphamide, or rituximab[18]
Trimethoprim-sulfamethoxazole: Single-strength daily or double-strength TIW
Alternatives: Dapsone 100mg daily (check G6PD), atovaquone 1500mg daily, or inhaled pentamidine

Oyster: PJP risk persists 3-6 months after stopping high-risk medications. Continue prophylaxis during this window.

Hepatitis B Reactivation:

Screen all patients before rituximab, TNF-α inhibitors, JAK inhibitors[19]
Test: HBsAg, anti-HBc, anti-HBs
HBsAg positive: Entecavir or tenofovir prophylaxis throughout therapy + 12 months post-cessation
HBsAg negative/anti-HBc positive (past infection): Monitor HBV DNA or consider prophylaxis for high-risk drugs (rituximab)

Fungal Infections:

Endemic mycoses (histoplasmosis, coccidioidomycosis, blastomycosis): Consider geographic risk with TNF-α inhibitors
Invasive aspergillosis: Rare but reported with high-dose steroids + other immunosuppressants
Candida: Increased risk with prolonged antibiotics and glucocorticoids

Viral Infections:

Herpes zoster: Dramatically increased with JAK inhibitors (consider vaccination pre-treatment with Shingrix)[15]
CMV reactivation: Rare except with high-dose steroids + rituximab or cyclophosphamide
COVID-19: Higher severity in rituximab, JAK inhibitor, mycophenolate users—vaccination critical[20]

Perioperative Infection Prevention Strategies

Preoperative Optimization:

Achieve disease remission when possible before elective surgery
Minimize glucocorticoid dose (target <10mg prednisone equivalent)
Complete vaccination (pneumococcal, influenza, herpes zoster) ≥4 weeks before biologics
Address modifiable risk factors: glucose control, smoking cessation, nutritional status
Antibiotic prophylaxis: Standard surgical prophylaxis protocols apply; no modifications needed for immunosuppression

Pearl: Live vaccines are contraindicated during biologic therapy and high-dose immunosuppression. Plan vaccinations during disease quiescent periods before intensifying therapy.

Intraoperative Considerations:

Standard surgical aseptic technique
Maintain normothermia
Judicious use of implanted materials (consider infection risk vs. benefit)

Postoperative Surveillance:

High index of suspicion for infection—fever may be blunted by steroids
Low threshold for imaging and cultures
Consider atypical pathogens in deteriorating patients
Daily wound assessment in high-risk patients

The ICU Patient with Suspected Infection

Diagnostic Approach:

Broad initial workup: Blood cultures (2 sets), respiratory cultures, urine culture, wound cultures
Consider opportunistic pathogens: PJP (bronchoscopy with BAL if hypoxemic), fungal cultures/antigens (galactomannan, β-D-glucan)
CT imaging earlier than standard patients (subtle findings significant)
Serum biomarkers: Procalcitonin less reliable (may be blunted), CRP trends useful

Empiric Antibiotic Principles:

Broad-spectrum coverage including MRSA, Pseudomonas
Add PJP coverage (TMP-SMX high-dose) if respiratory failure + ground-glass opacities + CD4 <200 or recent rituximab/cyclophosphamide
Consider antifungal coverage (voriconazole or echinocandin) in high-risk patients with persistent fever despite antibiotics
Lower threshold for empiric antivirals (acyclovir for HSV/VZV if vesicular lesions or unclear encephalopathy)

Hack: In rituximab-treated patients with hypoxemic respiratory failure, PJP and CMV can coexist. Consider both empirically while awaiting BAL results. CMV PCR from BAL fluid aids diagnosis.

Balancing Immunosuppression in Acute Illness

Continue or Stop DMARDs?

Serious infection: Hold biologics, JAK inhibitors, and conventional DMARDs (except hydroxychloroquine) until infection resolving
Maintain maintenance steroids (adrenal insufficiency risk)
Resume therapy after clinical improvement and appropriate antimicrobial therapy duration

Oyster: Paradoxically, abrupt DMARD cessation can precipitate disease flare, which itself increases infection risk and complicates management. Case-by-case assessment with rheumatology consultation is ideal.

Conclusion: The Critical Care Synthesis

Managing rheumatology patients perioperatively demands integration of pharmacokinetic principles, physiologic stress response understanding, and infection risk stratification. Key tenets include:

Individualize biologic DMARD timing based on half-lives while balancing flare risk
Assume HPA axis suppression in chronic steroid users and provide appropriate stress coverage
Maintain high suspicion for opportunistic infections and employ risk-stratified prophylaxis
Multidisciplinary collaboration with rheumatology, surgery, and infectious disease optimizes outcomes

The perioperative period represents both vulnerability and opportunity—vulnerability to infection and disease flare, but opportunity for optimization through evidence-based management. As our therapeutic armamentarium expands, so must our sophistication in navigating these complex clinical scenarios.

References

Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol. 2017;69(8):1538-1551.
Barbacki A, Pineau CA, Vinet E, et al. Perioperative Management of Biologic Agents in Patients with RA, SpA, PsA, or JIA: A Systematic Literature Review Informing the 2021 American College of Rheumatology Guideline. Arthritis Rheumatol. 2022;74(5):730-746.
Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor. Ann Rheum Dis. 2021;80(2):185-195.
Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-920.
Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res. 2022;74(9):1399-1408.
Winthrop KL, Curtis JR, Lindsey S, et al. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol. 2017;69(10):1960-1968.
Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60(3):214-217.
Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-735.
Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R139.
Woods CP, Argese N, Chapman M, et al. Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. Eur J Endocrinol. 2015;173(5):633-642.
Liu MM, Reidy AB, Saatee S, Collard CD. Perioperative Steroid Management. Anesthesiology. 2017;127(1):166-172.
Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg. 2008;143(12):1222-1226.
Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143.
Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of Immunoglobulin Levels With Infection Risk in Patients Treated With Rituximab. JAMA Netw Open. 2018;1(7):e184169.
Winthrop KL, Nash P, Yamaoka K, et al. Safety and Immunogenicity of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Receiving Tofacitinib Therapy. Arthritis Rheumatol. 2021;73(11):1967-1975.
Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265.
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;10:CD005590.
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-244.
Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942.

Conflict of Interest: None declared